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Mini-Abstract 
A continuous improvement of the survival results of hepatectomy for hepatocellular 
carcinoma was observed in the past 20 years. The improvement was seen in patients 
with cirrhosis, those undergoing major hepatectomy, and those with liver tumors of 
TNM stages II, IIIA and IVA. 
Structured Abstract 
Objective: To investigate the trend of the post-hepatectomy survival outcomes of 
hepatocellular carcinoma (HCC) patients by analysis of a prospective cohort of 1198 
patients over a 20-year period. 
Summary Background Data: The hospital mortality rate of hepatectomy for HCC 
has improved but the long-term survival rate remains unsatisfactory. We reported an 
improvement of survival results 10 years ago. It was not known whether there has 
been further improvement of results in recent years. 
Methods: The patients were categorized into two 10-year periods: period 1, before 
1999 (group 1, n=390) and period 2, after 1999 (group 2, n=808). Patients in group 2 
were managed according to a modified protocol and technique established in previous 
years.  
Results: The patients in group 2 were older and had a higher incidence of co-morbid 
illness and cirrhosis. They had a lower hospital mortality rate (3.1% vs. 6.2%, p = 
0.012) and longer 5-year overall survival (54.8% vs. 42.1%, p < 0.001) and 
disease-free survival rates (34.8% vs. 24%, p = 0.0024). An improvement in the 
overall survival rate was observed in patients with cirrhosis, those undergoing major 
hepatectomy, and those with tumors of TNM stages II, IIIA and IVA. A significant 
increase in the survival rates was also seen in patients whose tumors were considered 
transplantable by the Milan criteria (72.5% vs. 62.7%, p = 0.0237). Multivariate 
analysis showed a significantly more favorable patient survival for hepatectomy in 
period 2. 
Conclusions: A continuous improvement of survival outcomes after hepatectomy for 
HCC was achieved in the past 20 years even in patients with advanced diseases. 
Hepatectomy remains the treatment of choice for resectable HCC in a predominantly 
HBV-based Asian population. 
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Hepatocellular carcinoma (HCC) is one of the most lethal malignancies. Liver transplantation 
is the best treatment for HCC but is limited by the number of deceased organ donations. Even 
with the application of living donor liver transplantation, not many patients can benefit from 
the procedure.1 In Asia, resection of HCC remains the treatment of choice for potentially 
curable diseases. Resection of HCC is not without risk, especially in the presence of cirrhosis. 
Nevertheless, the results of resection of HCC have been steadily improving. In 1999, we 
reported the first series of hepatectomy for HCC without hospital mortality.2 In 2000, we 
reported an improved long-term survival rate over a 10-year period.3 In the last 10 years, we 
continued to refine the surgical technique, expand the indications of hepatectomy and 
improve perioperative care. This study evaluated whether there was further improvement of 
the survival results since our last reports. 
 
PATIENTS AND METHODS 
Between 1989 and 2008, 1198 consecutive patients underwent resection of HCC at the 
Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 
China. The patients were managed and operated according to a protocol previously 
established.2 Further modifications have been made in recent years (Table 1). All data were 
collected prospectively by a single research assistant. The patients were categorized into two 
10-year periods: before December 1998 (period 1, patients designated as group 1, n=390) and 
after January 1999 (period 2, patients designated as group 2, n=808). 
 
Preoperative Management 
The patients were selected for resection based on assessments of the general condition, tumor 
status, liver function and remnant liver volume. The criteria for resectability on imaging were: 
absence of extrahepatic metastasis, anatomically suitable and technically feasible disease, and 
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absence of main portal vein or inferior vena cava (IVC) tumor thrombus. Involvement of the 
first-ordered branch of the portal vein to the junction with the contralateral branch and 
common hepatic duct and bilobed involvement did not preclude resection. Partial resection of 
the IVC was performed if the IVC was invaded by the tumor. A tumor near to the main 
drainage vein of the remnant liver was accepted for major hepatectomy if reconstruction of 
the hepatic vein was technically feasible. Computed tomography (CT) volumetry was 
performed if the remnant liver volume was estimated insufficient for postoperative recovery. 
Patients with remnant liver volume less than 30% underwent portal vein embolization of the 
ipsilateral lobe to induce contralateral lobe hypertrophy.4 Liver function assessment was 
based largely on the results of the indocyanine green (ICG) clearance test. An ICG retention 
rate of 14% at 15 minutes after intravenous injection was acceptable for major hepatectomy. 
For minor hepatectomy, the cut-off value was 22%.5 
   
On the day before surgery, the patient was given a light meal. In the evening, the bowel was 
washed out with Phospho-soda buffered oral saline laxative (Fleet; CB Fleet Co., Inc. 
Lynchburg, VA). Bowel washout was performed in case en bloc resection of the HCC with 
the colon was required and it could also reduce the discomfort arising from poor bowel 
movement in the immediate postoperative period. Antibiotic and a proton pump inhibitor 
were given at the time of induction of general anesthesia. 
 
Surgical Techniques 
Surgery was performed through a bilateral subcostal incision with an upward midline incision 
in most of the patients. Intraoperative ultrasonography was performed routinely as in the 
previous protocol to detect additional tumors in the liver, to define the topographic 
relationship of the tumor with major vascular pedicles and its possible invasion, and to 
determine the plane of liver transection and the width of the tumor-free resection margin.2 
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Liver transection was performed mainly with the ultrasonic dissector. In period 2, a new 
model of ultrasonic dissector was used. The change included an incorporation of 
electrocautery into the tip of the instrument and reduction in the lumen size of the ultrasonic 
dissector tip from 2 mm to 1 mm, which allowed precise dissection of intrahepatic structures 
and immediate coagulation of fine branches exposed by the ultrasonic dissector. The use of 
the ultrasonic dissector allowed exposure of major intrahepatic portal pedicles and hepatic 
vein that served as an important anatomic landmark for a precise hepatectomy.6 During the 
operation, meticulous attention was paid to protect the liver remnant by avoiding prolonged 
liver rotation and liver compression by the retractor and inflow vascular occlusion. 
Preservation or reconstruction of the major hepatic vein was also required to avoid liver 
congestion.7 Liver rotation from the right side to the left side for exposure of the IVC and 
resection of a tumor in the segment 6 or 7 was intermittent, similar to the Pringle maneuver. 
During liver transection, the central venous pressure was maintained at a low level (< 5 mm 
Hg) by restricting intravenous fluid administration to reduce bleeding.8 Fluid replacement 
was performed once the liver transection was completed. Intermittent Pringle maneuver was 
not employed routinely in period 2 unless the liver transection was difficult due to venous 
congestion and inability to reduce the central venous pressure (in the situation of concomitant 
cardiac valvular disease or elderly patients). Hemostasis was achieved by electrocautery, 
argon beam coagulation and suturing. Argon beam coagulation was avoided at the site of 
suturing to reduce the chance of dislodgment of ligature. Large bite suturing was avoided to 
reduce the errors of occluding the major hepatic vein or its branches. Bile leakage from the 
transection surface, hilar plate and portal pedicle was checked by dilute methylene blue 
instillation into the bile duct via a cystic duct cannula (without common bile duct occlusion) 
or by compression onto the transection surface by a piece of clean gauze. Thorough irrigation 
was made to remove debris and clots. The wound was not closed until a pool of irrigant at the 
site of transection was totally clear. Abdominal drain was not deployed unless there was 
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doubt about bile leakage.9 Before wound closure, local anesthetic (bupivacaine, 3 mg/kg) was 
used to infiltrate the wound at the plane between the peritoneum and abdominal muscle. 
 
Postoperative Care 
After surgery, the patients, particularly those with cirrhosis and major hepatectomy, were 
monitored in the intensive care unit (ICU) with attention to the fluid balance, oxygenation 
and tissue perfusion. Patients with evidence of fluid retention, low urine outputs and low 
blood pressure were treated with low-dose noradrenaline rather than further fluid 
administration. Mechanical ventilation was given to patients after a prolonged operation, 
marginal liver function and unstable hemodynamics. All patients were given albumin and 
antibiotic for about 3 days. More potent antibiotic was given promptly once a sign of sepsis 
was detected. Incentive spirometry was performed in all patients to prevent atelectasis and 
pneumonia. Parenteral nutrition consisting of branched-chained amino acid-enriched solution, 
low-dose dextrose, medium- and long-chain triglycerides and phosphate was started 
immediately after hepatectomy in all patients with cirrhosis or major hepatectomy and was 
continued for 5 to 7 days by means of a central venous catheter inserted aseptically.10 Once 
parenteral nutrition was started, no other intravenous fluid was given so as to avoid liver 
congestion. For patients with diabetes mellitus and receiving parenteral nutrition, tight blood 
sugar control was achieved to reduce infection.11 
 
Adjuvant Therapy 
Postoperative adjuvant treatment for HCC was normally not given except in special 
circumstances. In group 1, 14 patients received chemoembolization for histologic margin 
involvement by the tumor and 30 patients were enrolled in a randomized trial of systemic 
epirubicin and chemoembolization.12 In group 2, 40 patients received interferon in a 
randomized trial and 4 patients received chemoembolization for involvement of resection 
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margin by the tumor.13 
 
Follow Up and Management of Recurrence 
All patients were followed up by the surgical team monthly in the first year and quarterly 
thereafter if no recurrence was detected. Only 25 patients defaulted the follow up. The first 
CT or magnetic resonance imaging (MRI) was performed about 1 month after hepatectomy 
and repeated about every 3 to 4 months in the first year and every 6 months in subsequent 
years. The diagnosis of recurrence was based on typical imaging findings on CT or MRI, and 
if necessary, percutaneous fine-needle aspiration cytology. Recurrences were treated 
aggressively using the multi-modality approach. Patients with anatomically resectable tumors 
and preserved liver function would be considered for re-resection. Otherwise, the tumors 
were treated by chemoembolization, alcohol injection, radiofrequency ablation, high intensity 
focused ultrasound14 or liver transplantation, depending on the location of the tumor and the 
liver function of the patient. Patients with extrahepatic recurrence were treated by resection if 
the lesion was solitary and anatomically feasible. For patients with multiple tumors, systemic 
chemotherapy was given only if the general condition of the patient was satisfactory. 
 
Statistical Analysis 
In this study, major hepatectomy was defined as resection of 3 or more liver segments 
according to the Couinaud nomenclature.15 Minor hepatectomy was defined as resection of 2 
or fewer liver segments. Hospital mortality was defined as death during the period while the 
patient was in the hospital for the hepatectomy. All complications were prospectively 
recorded and the severity was graded by the Clavien-Dindo classification.16 All HCCs were 
confirmed by histologic examinations. A positive resection margin was defined as the 
presence of tumor cells at the line of transection due to microscopic involvement by the main 
tumor, venous permeation or microsatellite nodules. A survival analysis was performed using 
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the time of hepatectomy to the date of death or last follow up. The end point of disease-free 
survival was recurrence of tumor or death (excluding hospital mortality). Seventeen patients 
in period 1 and 11 patients in period 2 had residual diseases at the time of hepatectomy. They 
were excluded in the disease-free survival analysis. The last censored date was 31 December 
2009. Continuous variables were expressed as median (range) and compared between groups 
by the Mann-Whitney U test. Discrete variables were compared by the 2 test. Survival 
curves were computed using the Kaplan-Meier method and compared between groups by the 
log-rank test. The logistic regression analysis was performed to define factors that affected 
hospital mortality. Cox proportional hazard models were performed to define factors that 
determined the overall and disease-free survival rates. All statistical analyses were made 
using the statistical software (SPSS 16 for Windows, SPSS Inc, Chicago, IL). Statistical 
significance was defined as p < 0.05. 
 
RESULTS 
Comparison of the two groups of patients showed that patients in the period 2 were older and 
had a higher incidence of co-morbid illness, but more patients in this group had 
asymptomatic tumors or tumors detected by screening (Table 2). The liver function in terms 
of Child-Pugh classification, ICG retention rate and international normalized ratio was 
similar between the two groups. The preoperative serum albumin and creatinine levels were 
lower and the serum bilirubin level was higher among the patients in group 2. 
 
In period 2, there were fewer patients with thoracic extension of skin incision. The incidence 
of tumor rupture, either spontaneous or iatrogenic, was lower among the patients in group 2. 
The need for major hepatectomy was also lower. For patients having right hepatectomy, the 
anterior approach was used predominantly in period 2 (28.6% vs. 62%, p < 0.001). The 
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ultrasonic dissector was used in almost all patients and the use of Pringle maneuver was 
limited to 16% of the patients in the second period (Table 3). The blood loss volume, 
transfusion volume and the percentage of patients having blood transfusion were significantly 
lower in the patients in group 2 whether it was major or minor hepatectomy. Abdominal drain 
was deployed in 20.9% of the patients in group 2. 
 
For the pathological status, while the tumor-node-metastasis (TNM) staging17 of the tumors 
of the two groups were similar, the patients in group 2 had smaller tumors (Table 4). The 
incidence of microvascular invasion was similar. The incidence of a tumor involving the 
resection margin was lower in group 2. More patients in group 2 had underlying cirrhosis. 
 
In the postoperative period, fewer patients in period 2 required mechanical ventilation. The 
complication rate was lower, especially for Clavien-Dindo grades IIIA and V severity. The 
hospital mortality rate of the patients in group 2 was significantly lower than that of the 
patients in group 1 (6.2% vs. 3.1%, p = 0.012). The reduction in the hospital mortality rate 
was seen mostly in cirrhotic patients (7.8% vs. 3.1%, p = 0.007). Both the ICU and hospital 
stay durations were shorter in group 2 (Table 5).  
 
By the logistic regression analysis, blood loss volume and preoperative serum creatinine level 
were the significant factors affecting the hospital mortality in group 1, whereas the need for 
blood transfusion, preoperative serum creatinine level, age and major hepatectomy were the 
significant factors for patients in group 2. For the entire group of patients, age (relative risk 
1.047, 95% coincidence interval 1.018–1.076, p = 0.001), blood loss (relative risk 1.185, 95% 
coincidence interval 1.07–1.31, p = 0.001), the need for blood transfusion (relative risk 2.055, 
95% coincidence interval 1.01–4.18, p = 0.047), preoperative serum creatinine level (relative 
risk 1.008, 95% coincidence interval 1.002–1.013, p = 0.007), and major hepatectomy 
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(relative risk 2.26, 95% coincidence interval 1.023–4.992, p = 0.044) were the significant 
factors predicting hospital mortality. 
 
Recurrence of tumors occurred in 78.2% of patients in group 1 and 60.2% of patients in 
group 2 (p < 0.001) after a median follow-up duration of 47.3 months and 35.4 months, 
respectively. The incidence of recurrence within the first year of hepatectomy and the pattern 
of recurrence were similar between the two groups (Table 6). For the treatment of 
intrahepatic recurrence, many more patients in group 2 had re-resection of tumors. 
Chemoembolization was the main treatment method in the patients in group 1. 
Radiofrequency ablation replaced alcohol injection almost totally as the major ablation 
method in group 2. For the treatment of extrahepatic recurrence, the incidence of resection 
was the same and fewer patients in group 2 had systemic chemotherapy. 
 
The 1-, 3- and 5-year overall survival rates of the patients in group 1 were 74.8%, 54.2% and 
42.1%, respectively and those of the patients in group 2 were 83.3%, 64.9% and 54.8%, 
respectively (p < 0.001; Figure 1A). The 1-, 3- and 5-year disease-free survival rates of the 
patients in group 1 were 53.1%, 33.2% and 24%, respectively, and those of the patients in 
group 2 were 59.4%, 41.4% and 34.8%, respectively (p=0.0024; Figure 1B). In terms of 
TNM staging, higher overall survivals rates were observed in the patients with stages II, IIIA 
and IVA diseases in group 2 (Figure 2A). The disease-free survival rates were also 
significantly higher in the patients with TNM stages II and IIIA in group 2 (Figure 2B). 
 
The survival analysis was performed with regard to the tumor status that was considered 
transplantable based on pathology findings. There was a significantly increased 5-year 
survival rate in the HCC patients with tumor status within the Milan criteria18 from 62.7% in 
period 1 to 72.5% in period 2 (Figure 3A). A similar increase in the disease-free survival rate 
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was seen (40.2% in group 1 and 49.2% in group 2; Figure 3B), although the difference did 
not reach statistical significance. 
 
The survival analysis was performed with respect to the extent of hepatectomy. The median 
survival duration of the patients in group 2 having major hepatectomy was longer than that of 
the patients in group 1 (52.5 months vs. 37.9 months, p = 0.0054; Figure 4A). A similar 
phenomenon was seen in patients having minor hepatectomy (100.3 months vs. 56.83 months, 
p = 0.0002; Figure 4B). For disease-free survival, however, a significant increase was seen in 
patients having minor hepatectomy only (32 months vs. 20 months, p = 0.0028; Figures 4C 
and 4D). 
 
Major hepatectomy was performed mostly in patients with TNM stage III and IV tumors 
(69.4% of group 1 and 70.5% of group 2). The overall 5-year survival rates of TNM stage III 
and IV patients having major hepatectomy of group 1 and 2 patients were 25.4% and 36.6%, 
respectively (p = 0.0034). The 5-year disease-free survival rate was also higher, in period 2 
though the difference did not reach statistical significance (11.0% vs. 19.5%, p = 0.0675). 
 
The survival analysis was also performed in groups of patients with different underlying 
diseases. An improved overall survival rate was seen in the patients in group 2 who had 
underlying cirrhosis or normal liver (Figure 5). 
 
For patients receiving treatments for their recurrences, the patients in group 2 had longer 
post-treatment survival, though the difference was not significant (Table 6). 
 
Further survival analysis was performed by grouping the patients into four 5-year sequential 
periods. A steady and significant improvement in the overall and disease-free survival rates 
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was seen (Figure 6). 
 
By univariate and multivariate analyses, blood loss volume (> 2 liters), tumor nodule number 
(> 1), cirrhosis, venous invasion and TNM stage were the significant factors influencing the 
disease-free survival of the patients in group 1. For the patients in group 2, significant factors 
identified were symptomatic presentation, number of tumor nodule (> 1), microvascular 
invasion, positive resection margin and TNM stage. For the entire group, symptomatic 
presentation, blood loss (> 2 liters), number of tumor nodule (> 1), positive resection margin, 
microvascular invasion and TNM stage were the significant factors influencing the 
disease-free survival (Tables 7 and 8). 
 
Significant factors identified for predicting overall survival were similar to those for 
predicting disease-free survival except that the ICG retention rate (> 14%) and development 
of postoperative complications were additional factors for groups 1 and 2, respectively. For 
the entire group, symptomatic presentation, blood loss volume (> 2 liters), postoperative 
complication, number of tumor nodule (> 1), positive resection margin, venous invasion and 
TNM stage were the significant factors (Tables 8 and 9). In addition, the period in which the 
patients were operated was one of the determinants of survival. Patients operated in the 
second period had 61.5% longer median survival duration than that of the patients in the first 
period. 
 
DISCUSSION 
In this study, we demonstrated an improvement of the results of hepatectomy for HCC 
despite an older patient population, a higher incidence of co-morbid illness, a higher 
incidence of cirrhosis, and worse liver function in patients operated in the second 10-year. 
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The reduction in the hospital mortality rate was particularly obvious in cirrhotic patients. It 
was associated with less intraoperative bleeding and blood transfusion irrespective of the 
extent of hepatectomy, shorter intensive care unit and hospital stays, and a lower 
complication rate. The improvement in the long-term survival was also observed in patients 
with underlying cirrhosis and even in patients with advanced TNM stages who underwent 
major hepatectomy. Since the operations were performed by the same team of surgeons, the 
accumulated experience was definitely a contributory factor but constant attention to 
refinement of the surgical technique and perioperative care were important reasons. 
 
With strict selection of HCC patients for hepatectomy basing on their liver function, 
preoperative renal function became an important factor influencing hospital mortality. 
Careful scrutiny of patients’ renal function was therefore mandatory. Patients with impaired 
renal function should be cared in the ICU for fluid balance control and considered for 
perioperative hemodialysis. Blood loss was also identified consistently to be an important 
factor predisposing to hospital mortality. Bleeding usually occurred during liver transection. 
Thus, the Pringle maneuver was a routine procedure in our early series and is currently used 
in many centers.19-21 However, in our recent practice, the Pringle maneuver has not been used 
routinely during liver transection because we found that without the time constraint of the 
Pringle maneuver, liver transection is unhurried and precise. Without the Pringle maneuver, a 
lower bleeding and transfusion volume can actually be achieved even in patients undergoing 
major hepatectomy. The reduction in bleeding volume is accomplished by the cautious and 
slow application of the ultrasonic dissector and the restriction of intravenous fluid infusion to 
reduce the central venous pressure. However, older patients are at a higher risk of having 
more bleeding during liver transection because it is difficult to maintain normal blood 
pressure with a low central venous pressure. Patients with renal impairment have a higher 
risk of postoperative renal failure if fluid infusion is restricted. We have also observed that a 
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low central venous pressure is ineffective because tumor compression on the hepatic veins or 
iatrogenic and premature division of the outflow tract are responsible for liver congestion. In 
such situations, Pringle maneuver is employed to achieve rapid liver transection and 
minimum blood loss. 
 
The incidence of postoperative complication remained high, even though it was lower in the 
second period. Considering the nature of the operation, postoperative complications seemed 
inevitable. However, with careful postoperative management and possibly improved 
technique, the incidence of complications, particularly Clavien-Dindo grades IIIa and V 
severity, were reduced in period 2. Infection remained an important cause of rapid 
deterioration of liver function of HCC patients after hepatectomy. In our current protocol, 
systemic antibiotic is normally given for 3 to 5 days despite the sterile nature of the operation 
because contamination may occur during the operation and presence of a thin layer of 
ischemic liver at the transection site, though minimal, may be the source of occult infection. 
Pneumonia is the most common infection and should be prevented at all costs. Once a sign of 
infection appeared, we modified the antibiotic protocol promptly and looked for the source of 
infection. If hyperglycemia was noted, tight blood sugar control was considered mandatory.11 
With early intervention, further deterioration could be withheld. However, control of 
infection is possible only if the liver function is preserved. That attests the need for 
preservation and protection of the liver remnant during the operation.5,7 
 
Pathologic characteristics of the tumor such as microvascular invasion, multiplicity and TNM 
stage remain the major determinants of long-term survival. In this study, solitary tumor was 
associated with favorable prognosis but tumor size was not a significant factor. Thus, the 
higher incidence of smaller tumors in the patients in group 2 could not account for better 
survival rates. A further implication is that hepatectomy for a solitary tumor irrespective of 
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the tumor size is a worthwhile procedure.22,23 Large tumors, however, frequently impinge on 
the major hepatic veins or the liver hilum. Resection of a large tumor yet preserving blood 
supply and venous drainage of the remnant liver is feasible as long as high quality CT or MRI 
is available for careful planning of the operation. Restoration of the portal vein and hepatic 
vein is possible nowadays with conduits such as the cryopreserved vein or ringed Gor-Tex 
graft. 
 
In the second period of the study, more patients presented with asymptomatic tumors that 
were detected by screening. They had higher survival rates. On the contrary, patients with 
symptomatic presentation had less favorable survival outcomes. In these patients, symptoms 
were produced because of the rapidly increasing tumor size related to fast tumor growth or 
intra-tumoral bleeding, both indicative of aggressive biological behaviors. Fortunately, the 
incidence of ruptured HCC being associated with even worse prognosis was lower in period 2. 
To offer the patients the maximum survival benefits, we operated on symptomatic patients 
early and avoided intraoperative tumor rupture.24 Thus, the overall survival duration of 
symptomatic patients was longer in the second period (Table 9). A similar increase in the 
survival rate was also observed in asymptomatic patients (Table 9). Hence, a higher incidence 
of asymptomatic patients in the second period may not be an important reason for the 
improvement of the results. 
 
Blood loss volume was consistently found to influence the long-term survival in the first 
period, but with meticulous efforts to reduce bleeding, blood loss volume was not a 
significant factor in the second period. Blood transfusion, however, is still needed in some 
patients with difficult hepatectomy. Unlike the pathological factors, bleeding and transfusion 
are surrogate markers of technical factors that can be modified.25 Another technical factor is 
the tumor-free resection margin. Positive resection margin, though lower in incidence in 
 14
period 2 of the current study, has a profound influence on the long-term survival. The width 
of the macroscopic tumor-free resection margin needed to avoid microscopic positive 
resection margin and local recurrence is controversial. There are suggestions that the width of 
the tumor-free resection margin is irrelevant because HCC is potentially multifocal and 
microscopic involvement of the margins is related to the aggressive behaviors of the 
tumor.26-28 Moreover, tumors encroaching the major hepatic vein or the portal pedicle may 
not have sufficient tumor-free resection margins if preservation of the remnant liver volume 
is needed. Yet, meticulous attention to achieve tumor free resection margin in situations other 
than those involving the liver hilum seems warranted.  
 
Postoperative complications did influence the overall long-term survival rate. The exact 
reason is not known. It is not impossible that complications such as bleeding and infection are 
frequently associated with systemic inflammatory response. The latter phenomenon may 
produce a favorable microenvironment in the liver remnant and extrahepatic organs for 
circulating cancer cells to deposit and grow.29 Septic complications, therefore, must be 
prevented at all costs. To prevent cancer cell disseminating into the systemic circulation, the 
“no touch” technique such as the anterior approach right hepatectomy is preferred.23 The 
anterior approach is also applicable to left liver resection.30 
 
Both the disease-free and overall survival rates have improved but the overall survival rate 
was much higher than the disease-free survival rate in the second period even for late TNM 
stage diseases. This was due to our aggressive treatment for both intra- and extra-hepatic 
recurrences. Treatment of recurrence is more likely to be associated with better outcomes if 
the recurrence is small and few and treatment is prompt. Only a close follow up and 
surveillance imaging can detect early recurrence. However, the median survival duration of 
patients treated for their recurrence was not significantly longer than patients in group 1. This 
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implies that the current liver tumor ablation treatment (including radiofrequency ablation and 
chemoembolization) cannot not completely control all tumor growth or prevent further 
recurrences and their efficacy has not changed over the years. Further studies to refine local 
ablation treatments and design of strategies to eradicate microscopic tumor foci are needed. 
 
In this study, hepatitis B is the predominant cause of HCC, whereas hepatitis C and 
alcoholism are rare etiologies. Thus, it is impossible to demonstrate whether improvement of 
results occurred in patients with etiologies other than hepatitis B. Nevertheless, compared 
with the reported series with hepatitis C as the predominant etiology, the results of the current 
series appeared more favorable.31 Availability of effective treatments of hepatitis B may 
account for the difference.32 The other deficiencies of this study is the possibility of lead-time 
bias and inability to classify patients preoperatively into the Milan criteria accurately. With 
improved imaging modalities, accurate classification of tumor staging is anticipated.33 
 
In summary, a continuous improvement of hospital mortality and long-term survival results 
was observed in the past 20 years in HCC patients having hepatectomy. The improvement is 
in pace with that of liver transplantation for HCC.34 The overall survival rate of patients with 
tumor status that is considered transplantable after hepatectomy is comparable with that 
accomplished by liver transplantation.35 Although the disease-free survival rate of such 
patients is far below that of the transplant patients, prompt treatment of recurrence detected 
by vigorous postoperative surveillance did result in long-term survival. Thus, hepatectomy 
should remain the treatment of choice for resectable HCC and preserved liver function in 
regions with deceased organ scarcity. Improvement of survival was also observed in patients 
with advanced diseases. The 5-year overall survival rates of 81.7%, 77.2%, 44%, and 28.2% 
for TNM stages I, II, IIIA, and IVA patients after hepatectomy, respectively, may become the 
current standard. Further improvement of results depend on technical refinement to reduce 
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blood loss to the minimum, avoid blood transfusion, preserve liver remnant function, secure 
tumor-free resection margins, and meticulous perioperative care to reduce complications. 
Life-long surveillance for recurrence and prompt treatment are mandatory but development 
of more effective local ablation methods are needed to lengthen post-recurrence survival. 
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FIGURE LEGENDS 
Figure 1. Comparison of A, overall survival rates and B, disease-free survival rates of HCC 
patients after hepatectomy between patients in group 1 (1989–1998) and group 2 
(1999–2008). 
 
Figure 2. Comparison of A, the overall survival rates and B, the disease-free survival rates of 
HCC patients after hepatectomy by TNM stage. 
 
Figure 3. Comparison of A, the overall survival rates and B, the disease-free survival rates of 
HCC patients whose tumors were within the Milan criteria after hepatectomy. 
 
Figure 4. Comparison of A, B, the overall survival rates and C, D, the disease-free survival 
rates of HCC patients having major or minor hepatectomy between patients in group 1 and 
group 2. 
 
Figure 5. Comparison of the overall survival rates of HCC patients after hepatectomy with 
underlying A, cirrhosis, B, chronic hepatitis and C, normal liver. 
 
Figure 6. Comparison of A, the overall survival rates and B, the disease-free survival rates of 
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HCC patients operated in 4 sequential periods. 
 
 
Table 1. Major changes in the management protocol. 
 
 Period 1 Period 2 
Preoperative assessment Indocyanine green clearance test Indocyanine green clearance test 
Serum creatinine < 150 mol/l 
Intraoperative procedure Pringle maneuver No Pringle maneuver except in difficult liver transection 
 Thoraco-abdominal incision Avoidance of unnecessary thoraco-abdominal incision 
 Ultrasonic dissector Reduction in lumen size of the tip and incorporation of electrocautery 
 Middle hepatic vein not exposed to avoid bleeding Exposure of the middle hepatic vein as a guide to precise right or left 
hepatectomy 
 Abdominal drainage Abdominal drainage only if bile leakage is anticipated 
 -- Infiltration of wound by local anesthetic before closure 
Postoperative care -- Low dose inotrope if blood pressure is low (after excluding bleeding) 
Tight control of blood sugar level (< 8 mmol/l 
Incentive spirometry 
Table
Table 2. Comparison of preoperative data. 
 
 Group 1 
(n=390) 
Group 2 
(n=808) 
P value 
Age (year) 54 (5–82) 56 (13–86) 0.003 
Male : Female 325 : 65 648 : 160 0.193 
Presence of co-morbid illness 108 (27.7%) 318 (39.4%) < 0.001 
Asymptomatic HCC 130 (33.3%) 405 (50%) < 0.001 
HCC detected by screening 71 (18.2%) 284 (35.1%) < 0.001 
Child-Pugh class 
 A 
 B 
 
374 (95.9%) 
16 (4.1%) 
 
774 (95.8%) 
34 (4.2%) 
 
0.932 
MELD score 
    All patients 
    Cirrhosis 
    Chronic hepatitis 
 
7.61 (6–17) 
8.08 (6–17) 
7.5 (6–14) 
 
7.61 (6–20) 
7.68 (6–20) 
7.69 (6–15) 
 
0.21 
0.003 
0.12 
Indocyanine green retention (15 min) rate (%) 11.3 (1.5–66.9) 11.4 (1.2–78) 0.914 
Platelet count (109/l) 174 (34–667) 179 (27–713) 0.127 
Serum albumin (g/l) 41 (23–53) 40 (17–56) < 0.001 
Serum bilirubin (µmol/l) 11 (2–63) 12 (2–61) 0.003 
International normalized ratio 1 (0.8–1.5) 1 (0.8–1.6) 0.92 
Serum creatinine (µmol/l) 90 (34–204) 87 (35–839) < 0.001 
Serum alpha-fetoprotein (ng/ml) 230 (2–1,335,900) 82 (1–1,112,000) < 0.001 
Hepatitis B 323 (82.8%) 700 (86.6%) 0.07 
Preoperative portal vein embolization 0 31 (3.8%) < 0.001 
HCC, hepatocellular carcinoma 
 Table 3. Comparison of operation data. 
 
 Group 1 
(n=390) 
Group 2 
(n=808) 
P value 
Incision with thoracic extension 58 (14.9%) 84 (10.4%) 0.025 
Tumor rupture 38 (9.7%) 41 (5.1%) 0.002 
Resection 
 Major hepatectomy 
 Minor hepatectomy 
 
268 (68.7%) 
122 (31.3%) 
 
465 (57.5%) 
343 (42.5%) 
 
< 0.001 
Anterior approach right hepatectomy 65 (16.7%) 222 (27.5%) < 0.001 
Pringle maneuver 205 (52.6%) 134 (16.6%) < 0.001 
Use of ultrasonic dissector 279 (71.5%) 748 (92.6%) < 0.001 
Blood loss (l) 
 Major hepatectomy 
 Minor hepatectomy 
1.5 (0.1–20) 
1.7 (0.2–20) 
1 (0.1–7) 
0.7 (0.01–15) 
0.92 (0.1–15) 
0.5 (0.01–5)  
< 0.001 
< 0.001 
< 0.001 
Blood transfusion (l) 
 Major hepatectomy 
 Minor hepatectomy 
0.43 (0–9.9) 
0.6 (0–9.9) 
0 (0–9) 
0 (0–3.84) 
0 (0–3.84) 
0 (0–2.4) 
< 0.001 
< 0.001 
< 0.001 
No. (%) of patients with blood transfusion 
 Major hepatectomy 
 Minor hepatectomy 
216 (55.4%) 
163 (60.8%) 
53 (43.4%) 
110 (13.6%) 
87 (18.7%) 
23 (6.7%) 
< 0.001 
< 0.001 
< 0.001 
Abdominal drain 333 (85.4%)  169 (20.9%) < 0.001 
Laparoscopic resection 0 26 (3.2%) 0.196 
Resection of portal vein / thrombectomy 20 (5%) 52 (6.4%) 0.372 
Resection of inferior vena cava 9 (2.3%) 12 (1.5%) 0.309 
 
 
 Table 4. Comparison of pathology data. 
 
 Group 1 
(n=390) 
Group 2 
(n=808) 
P value 
Cirrhosis 193 (49.5%) 488 (60.4%) < 0.001 
Chronic hepatitis 143 (36.7%) 219 (27.1%)  
Normal liver 54 (13.8%) 101 (12.5%)  
Tumor size (cm) 7.5 (0.5–25) 5.3 (0.7–28) < 0.001 
Number (%) patients with solitary tumor 270 (69.2%) 585 (72.4%) 0.255 
Microvascular invasion 179 (45.9%) 396 (49%) 0.312 
Resection margin involved by tumor 38 (9.7%) 30 (3.7%) 0.01 
TNM stage I 
   II 
   IIIA 
   IVA 
21 (5.4%) 
141 (36.2%) 
121 (31%) 
107 (27.4%) 
70 (8.7%) 
269 (33.3%) 
269 (33.3%) 
200 (24.7%) 
0.290 
No. (%) of patients with tumor status 
within the Milan criteria 
110 (28.2%) 343 (42.4%) < 0.001 
Liver pathology of patients with tumor 
status within Milan criteria 
       Normal 
       Chronic hepatitis 
       Cirrhosis 
 
 
3 (2.7%) 
26 (23.6%) 
81 (73.6%) 
 
 
25 (7%) 
60 (17.4%) 
258 (75.2%) 
 
 
.106 
 
 Table 5. Comparison of postoperative data. 
 
 Group 1 
(n=390) 
Group 2 
(n=808) 
P value 
Mechanical ventilation 208 (53%) 139 (17.2%) < 0.001 
Intensive care unit stay (days) 2 (0–128) 1 (0–49) 0.001 
Overall complication rate 153 (39.2%) 200 (24.8%) < 0.001 
Severity of complications  
Clavien-Dindo grade IIIa 
  IIIb 
  IVa 
  IVb 
  V 
 
96 (24.6%) 
13 (3.3%) 
1 (0.26%) 
0 
23 (5.9%) 
 
124 (15.3%) 
20 (2.5%) 
12 (1.5%) 
3 (3.7%) 
23 (2.8%) 
 
< 0.001 
0.395 
0.072 
0.555 
0.01 
Hospital mortality rate 
 Major hepatectomy 
 Minor hepatectomy 
24 (6.2%) 
20 (7.5%) 
4 (3.3%) 
25 (3.1%) 
20 (4.3%) 
5 (1.5%) 
0.012 
0.070 
0.250 
Hospital mortality rate 
 Cirrhosis 
 Chronic hepatitis 
 Normal liver 
 
15 (7.8%) 
6 (4.2%) 
3 (5.6%) 
 
15 (3.1%) 
5 (2.3%) 
5 (5%) 
 
0.007 
0.354 
1.000 
Hospital stay (days) 12 (2–130) 10 (1–198) < 0.001 
Adjuvant treatment 54 (15.5%) 90 (11.1%) 0.185 
 
 Table 6. Comparison of follow-up data of patients without hospital mortality and residual 
tumor at hepatectomy. 
 
 Group 1 
(n=349) 
Group 2 (n=772) P value 
Median (range) follow-up duration (months) 47.3 
(1.2–244) 
35.4 
(0.4–131.8) 
< 0.001 
Overall recurrence rate 273 (78.2%) 465 (60.2%) < 0.001 
Recurrence within first year (%) 44.1 39.1 0.114 
Recurrence pattern 
 Intrahepatic 
 Extrahepatic 
 Both 
 
146 (53.5%) 
44 (16.1%) 
83 (30.4%) 
 
241 (51.8%) 
78 (6.7%) 
146 (31.3%) 
 
0.664 
0.817 
0.778 
First treatment for intrahepatic recurrence 
 Re-resection 
 Chemoembolization 
 Alcohol injection 
 Radiofrequency ablation 
 Liver transplantation 
 High Intensity Focused Ultrasound 
229 
12 (5.2%) 
136 (59.3%) 
18 (7.8%) 
6 (2.6%) 
3 (1.3%) 
0 
387 
45 (11.6%) 
181 (46.8%) 
1 (0.26%) 
64 (16.5%) 
2 (0.5%) 
4 
 
0.008 
0.002 
< 0.001 
< 0.001 
0.366 
0.302 
First treatment for extrahepatic recurrence 
 Resection 
 Systemic chemotherapy 
127 
25 (19.7%) 
34 (26.8%) 
224 
51 (22.8%) 
31 (13.8%) 
 
0.5 
0.003 
Median (range) survival duration after treatment 
of recurrence (months) 
29.13 
(1.13–239) 
33 
(0.3–123) 
0.1142 
Median (range) post-treatment survival duration 
of patients with intrahepatic recurrence only 
 
38.3 (2.8–193.2) 
 
48.5 (0.3–111.3) 
 
0.068 
Median (range) post-treatment survival duration 
of patients with extrahepatic recurrence only 
 
11 (1.23–239) 
 
37.2 (1.3–119.3) 
 
0.0515 
Median (range) overall survival duration 
(months) 
42.3 
(0.07-244.03) 
68.33 
(0.03-131.8) 
< 0.001 
Median (range) disease-free survival (months) 14.57 
(0.53-235.63) 
19.23 
(0.4-130.93) 
0.0024 
Median (range) overall survival duration 
(months) of patients with tumor within the 
Milan criteria 
85.67 
(0.07–241.5) 
112.93 
(0.03–131.8) 
0.0237 
Median (range) disease-free survival duration 
(months) of patients with tumor within the 
Milan criteria 
33.53 
(1.1–235.6) 
54.3 (0.97–130.9) 0.2659 
 Table 7. Univariate analysis of risk factors for disease-free survival. 
 
 Group 1 
(1989–1998) 
Group 2 
(1999–2008) 
Entire group 
(1989–2008) 
 Patient 
number 
Median 
survival 
(months) 
Patient 
number 
Median 
survival 
(months) 
Patient 
number 
Median 
survival 
(months) 
Symptomatic presentation 
 Yes 
 No 
 
227 
122 
 
8.93 
29.27* 
 
379 
393 
 
11.60 
41.33* 
 
606 
515 
 
10.27 
36.13* 
Co-morbid illness 
 No 
 Yes 
 
254 
95 
 
11.73 
22.00 
 
470 
302 
 
15.47 
32.00* 
 
724 
397 
 
14.47 
28.00* 
Alpha-fetoprotein (ng/ml) 
  500 
 > 500 
 
200 
145 
 
16.43 
8.47 
 
522 
247 
 
28.23 
9.1* 
 
722 
392 
 
23.7 
8.83* 
Blood loss 
  2 liters 
 > 2 liters 
 
224 
120 
 
21.20 
8.70* 
 
682 
88 
 
22.2 
7.7* 
 
906 
208 
 
21.97 
8.47* 
Blood transfusion 
 No 
 Yes 
 
168 
179 
 
22.67 
10.27* 
 
677 
95 
 
22.2 
7.7* 
 
845 
274 
 
22.27 
9.13* 
Postoperative complication 
 No 
 Yes 
 
224 
125 
 
14.83 
14.10 
 
600 
172 
 
21.93 
13.70 
 
824 
297 
 
19.17 
13.93* 
No. of tumor 
 Solitary 
 Multiple 
 
250 
99 
 
21.83 
6.63* 
 
566 
206 
 
35.33 
6.33* 
 
816 
305 
 
29.97 
6.57* 
Tumor size 
  5cm 
 > 5cm 
 
131 
218 
 
29.40 
9.10* 
 
391 
381 
 
44.60 
9.6* 
 
522 
599 
 
36.63 
9.23* 
Liver status 
 Non-cirrhotic 
 Cirrhotic 
 
178 
171 
 
15.87 
12.43* 
 
306 
466 
 
19.23 
19.17 
 
484 
637 
 
18.27 
16.97 
Resection margin 
 Not involved 
 Involved 
 
318 
31 
 
16.43 
4.53* 
 
746 
26 
 
20.40 
4.43* 
 
1064 
57 
 
19.03 
4.53* 
Microvascular invasion 
 Absent 
 Present 
 
192 
157 
 
29.97 
6.23* 
 
396 
376 
 
52.43 
8.03* 
 
588 
533 
 
42.5 
7.47* 
Tumor rupture 
 Absent 
 Present 
 
317 
32 
 
16.10 
3.63* 
 
737 
35 
 
21.73 
8.60* 
 
1054 
67 
 
19.17 
7.47* 
Tumor-node-metastasis stage 
 I/II 
 IIIA/IVA 
 
154 
195 
 
40.20 
6.07* 
 
333 
439 
 
75.23 
8.10* 
 
487 
634 
 
59.13 
7.57* 
Period 
 1989–1998 
 1999–2008  
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
349 
772 
 
14.57 
19.23* 
* p < 0.05, comparison within group 1, 2 or entire group 
 
 Table 8. Significant factors predicting survival by multivariate analysis. 
 
  Relative 
risk 
95% confidence 
interval 
P value 
Disease-free survival 
 
   
Group 1 Blood loss (> 2 liters) 1.103 1.039–1.170 0.001 
 No. of tumor nodule (> 1) 1.059 1.012–1.108 0.014 
 Cirrhosis 1.672 1.316–2.125 < 0.001 
 Microvascular invasion 1.508 1.155–1.969 0.003 
 Tumor-node-metastasis stage 1.394 1.201–1.618 < 0.001 
Group 2 Symptomatic presentation 1.283 1.059–1.555 0.011 
 No. of tumor nodule (> 1) 1.069 1.034–1.106 < 0.001 
 Microvascular invasion 1.459 1.160–1.836 0.001 
 Positive resection margin 1.839 1.195–2.830 0.006 
 Tumor-node-metastasis stage 1.421 1.232–1.638 < 0.001 
Entire group Symptomatic presentation 1.268 1.087–1.480 0.03 
 Blood loss (> 2 liters) 1.046 1.008–1.086 0.017 
 No. of tumor nodule (> 1) 1.069 1.041–1.098 < 0.001 
 Positive resection margin 1.372 1.017–1.849 0.038 
 Microvascular invasion 1.432 1.203–1.704 < 0.001 
 Tumor-node-metastasis stage 1.356 1.222–1.504 < 0.001 
     
Overall survival 
 
   
Group 1 Blood loss (> 2 liters) 1.104 1.060–1.149 < 0.001 
 Indocyanine green retention 
rate (> 14%) 
1.017 1.005–1.030 0.007 
 Cirrhosis 1.722 1.344–2.206 < 0.001 
 Tumor-node-metastasis stage 1.665 1.471–1.884 < 0.001 
Group 2 Symptomatic presentation 1.416 1.125–1.782 0.003 
 Postoperative complication 1.590 1.271–1.990 < 0.001 
 No. of tumor nodule 1.055 1.016–1.095 0.005 
 Positive resection margin 3.046 1.943–4.774 < 0.001 
 Microvascular invasion 1.603 1.233–2.085 < 0.001 
 Tumor-node-metastasis stage 1.557 1.331–1.822 < 0.001 
Entire group Symptomatic presentation 1.316 1.105–1.569 0.002 
 Blood loss (> 2 liters) 1.079 1.043–1.116 < 0.001 
 Postoperative complication 1.252 1.061–1.478 0.008 
 No. of tumor nodule 1.047 1.018–1.076 0.001 
 Positive resection margin 1.386 1.030–1.866 0.031 
 Microvascular invasion 1.379 1.148–1.656 0.001 
 Tumor-node-metastasis stage 1.476 1.325–1.644 < 0.001 
 Period (1989 – 1998) 1.200 1.013–1.421 0.035 
 
 Table 9. Univariate analysis of risk factors for overall survival. 
 
 Group 1 
(1989–1998) 
Group 2 
(1999–2008) 
Entire group 
(1989–2008) 
 Patient 
number 
Median 
survival 
(months) 
Patient 
number 
Median 
survival 
(months) 
Patient 
number 
Median 
survival 
(months) 
Age 
  60 
 > 60 
 
261 
129 
 
42.80 
41.27* 
 
502 
306 
 
79.10 
63.13 
 
763 
435 
 
62.80 
53.93* 
Symptomatic presentation 
 Yes 
 No 
 
260 
130 
 
30.97 
69.20* 
 
403 
405 
 
41.33** 
112.93*† 
 
663 
535 
 
37.37 
100.3* 
Alpha-fetoprotein (ng/ml) 
  500 
 > 500 
 
220 
166 
 
45.73 
28.33 
 
548 
256 
 
79.10 
39.33* 
 
768 
422 
 
65.87 
37.37* 
Indocyanine green retention (15 
min) rate 
  14% 
 > 14% 
 
 
248 
127 
 
 
49.20 
32.87* 
 
 
537 
232 
 
 
67.93 
84.0 
 
 
785 
359 
 
 
60.07 
56.83 
Blood loss 
  2 liters 
 > 2 liters 
 
243 
141 
 
60.03 
26.00* 
 
709 
97 
 
77.80 
21.43* 
 
952 
238 
 
68.50 
25.30* 
Blood transfusion 
 No 
 Yes 
 
174 
214 
 
66.03 
29.00* 
 
698 
110 
 
82.07 
21.40* 
 
872 
324 
 
71.67 
26.13* 
Postoperative complication 
 No 
 Yes 
 
237 
153 
 
43.30 
37.90 
 
608 
200 
 
94.90 
43.27* 
 
845 
353 
 
65.93 
41.27* 
No. of tumor 
 Solitary 
 Multiple 
 
270 
120 
 
60.30 
18.57* 
 
585 
223 
 
96.20 
28.97* 
 
855 
343 
 
77.00 
25.67* 
Tumor size 
  5cm 
 > 5cm 
 
143 
247 
 
70.83 
32.80* 
 
401 
407 
 
106.67 
37.97* 
 
544 
654 
 
94.90 
34.83* 
Liver status 
 Non-cirrhotic 
 Cirrhotic 
 
197 
193 
 
49.23 
35.27* 
 
320 
488 
 
69.63 
65.93 
 
517 
681 
 
60.83 
58.57 
Resection margin 
 Not involved 
 Involved 
 
352 
38 
 
47.07 
13.40* 
 
778 
30 
 
73.13 
10.93* 
 
1130 
68 
 
63.70 
12.97* 
Microvascular invasion 
 Absent 
 Present 
 
211 
179 
 
66.03 
25.3* 
 
412 
396 
 
> 131.80 
34.10* 
 
623 
575 
 
104.20 
29.93* 
Tumor rupture 
 Absent 
 Present 
 
352 
38 
 
44.73 
19.03* 
 
767 
41 
 
77.00 
19.67* 
 
1119 
79 
 
63.80 
19.67* 
Tumor-node-metastasis stage 
 I/II 
 IIIA/IVA 
 
162 
228 
 
95.43 
23.00* 
 
339 
469 
 
> 131.80 
33.23* 
 
501 
697 
 
141.57 
29.77* 
Period 
 1989–1998 
 1999–2008  
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
390 
808 
 
42.30 
68.33* 
* p < 0.05, comparison within group 1, 2 or entire group 
** p=0.0116, comparison between groups 1 and 2 
† p=0.0082, comparison between groups 1 and 2 
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